How to access Zilbrysq from Qatar — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Qatari patient living with generalised myasthenia gravis (gMG) may receive a prescription for Zilbrysq (zilucoplan) from their treating neurologist or neuromuscular specialist. Zilbrysq is FDA-approved for gMG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive, and it is manufactured by UCB. It is a terminal complement C5 inhibitor delivered as a once-daily subcutaneous self-injection — a differentiated profile from IV or infusion-based C5 inhibitors like Soliris and Ultomiris, and from FcRn antagonists like Vyvgart and Rystiggo. In Qatar, Zilbrysq may not yet be broadly registered, which is why your neurologist may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.
The clinical situation
Zilbrysq is a macrocyclic peptide C5 inhibitor administered as a once-daily subcutaneous injection, weight-based (0.3 mg/kg). Because it inhibits terminal complement, it carries a US boxed warning regarding serious meningococcal infections, which is why meningococcal vaccination (or appropriate antibiotic prophylaxis if vaccination is not feasible in time) is a gating step before therapy begins, as is enrolment in the US REMS program. Internationally, equivalent manufacturer risk-minimisation measures apply. Your treating neurologist confirms diagnosis, vaccination status, and the daily injection plan per FDA labeling.
Is Zilbrysq legally importable into Qatar?
Yes — through the Qatar Ministry of Public Health (MoPH) Pharmacy and Drug Control Department's named-patient import framework. The pathway allows a Qatar-licensed physician to request import of a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally registered alternative is clinically equivalent for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.
For Zilbrysq specifically, international access respects the manufacturer's controlled-distribution expectations and the meningococcal-infection risk-minimisation gating.
How the pathway works, step by step
- Consultation with your treating neurologist. AChR antibody confirmation, gMG clinical diagnosis, MGFA classification, and meningococcal vaccination review.
- Meningococcal vaccination / prophylaxis. Vaccination at least 2 weeks before first dose, or antibiotic prophylaxis per labeling.
- MoPH named-patient application. Your physician files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner, aligned with the manufacturer's controlled-distribution model.
- Cold-chain shipment. Zilbrysq ships at 2–8°C with continuous temperature monitoring.
- Arrival and daily self-injection training. Your physician or clinic provides initial injection training; maintenance is daily self- or caregiver-administered.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming gMG diagnosis, AChR antibody positivity, MGFA class, and prior therapy history
- Verification of Qatar medical licence
- Patient identifier
- Meningococcal vaccination documentation or prophylaxis plan
- Planned daily injection regimen and projected monthly supply
- Injection-technique training plan
Reserve Meds provides a physician documentation kit that bundles the templates MoPH reviewers expect to see for complement inhibitors, including the meningococcal-infection risk-minimisation block.
Costs and timing
Zilbrysq's US cash-pay reference price sits in a broad indicative range — the annualised treatment cost falls in the USD 500,000–700,000 range in US list pricing because of daily dosing. International cold-chain logistics, MoPH documentation, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for the first dose after cohort intake opens is approximately 14–28 days from the moment a complete application is submitted (vaccination lead time may extend this).
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Zilbrysq specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody and aligned with the manufacturer's controlled-distribution program.
- Documentation. Regulatory package for your physician and for MoPH review, including the meningococcal-risk-minimisation block.
- Logistics. Cold-chain, temperature-monitored shipment.
- Concierge case lead. A named point of contact.
What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in Qatar? Yes, when executed through the MoPH named-patient framework with appropriate documentation.
What about the meningococcal warning? It is load-bearing. Vaccination at least 2 weeks before first dose, or antibiotic prophylaxis per labeling, is non-negotiable. Your physician coordinates this before treatment starts.
How does Zilbrysq compare with Vyvgart, Rystiggo, or Soliris? Zilbrysq is a daily subcutaneous self-injected C5 inhibitor. Soliris is a biweekly IV C5 inhibitor. Vyvgart and Rystiggo are FcRn antagonists delivered as periodic cycles (IV or SC). Your neurologist chooses based on mechanism preference, dosing burden, infusion access, and infection-risk profile.
Will private insurance cover this? Cash-pay is the default. Some Qatar private insurers reimburse gMG biologic therapy on escalated review; we supply documentation but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Zilbrysq coordination in Qatar.
Add me to the Zilbrysq waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.